Drugs & Targets FDA approves Oncomine Dx Target Test as CDx for Rybrevant December 10, 2021Vol.47 No.45
Drugs & Targets FDA accepts sBLA for BMS’ Reblozyl for priority review in adults with non-transfusion dependent beta thalassemia December 10, 2021Vol.47 No.45
Drugs & Targets M2GEN, Microsoft to collaborate on bioinformatics solutions for oncology December 10, 2021Vol.47 No.45
Drugs & Targets FDA approves Fyarro for malignant perivascular epithelioid cell tumor December 03, 2021Vol.47 No.44
Drugs & Targets FDA approves Darzalex Faspro, Kyprolis, and Dexamethasone for multiple myeloma December 03, 2021Vol.47 No.44
Drugs & Targets FDA approves Cytalux for identifying malignant ovarian cancer lesions December 03, 2021Vol.47 No.44
Drugs & Targets FDA grants orphan drug designation to UV1 cancer vaccine in metastatic melanoma December 03, 2021Vol.47 No.44
Drugs & Targets European Commission approves Keytruda plus Lenvima for patients with certain types of endometrial carcinoma December 03, 2021Vol.47 No.44
Drugs & Targets FDA approves Keytruda as adjuvant therapy for patients with RCC following nephrectomy November 19, 2021Vol.47 No.43
